Literature DB >> 21508735

Positron emission tomography/computed tomography in lung cancer staging, prognosis, and assessment of therapeutic response.

Mylene T Truong1, Chitra Viswanathan, Jeremy J Erasmus.   

Abstract

Positron emission tomography (PET)/computed tomographic scanning, using 18F-2-deoxy-D-glucose, complements conventional imaging evaluation of patients with lung cancer. The strength of PET scanning lies in the detection of nodal and extrathoracic metastases. PET scanning is also currently being studied in the assessment of prognosis and therapeutic response and has the potential to alter management of oncologic patients. This review will discuss the role of PET/computed tomographic scanning in the diagnosis, staging, and evaluation of prognosis and treatment response in patients with lung cancer.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21508735     DOI： 10.1097/RTI.0b013e3182128704

Source DB:  PubMed          Journal:  J Thorac Imaging        ISSN： 0883-5993            Impact factor:   3.000


  17 in total

Review 1.  PET-CT in Clinical Adult Oncology: II. Primary Thoracic and Breast Malignancies.

Authors:  Matthew F Covington; Bhasker R Koppula; Gabriel C Fine; Ahmed Ebada Salem; Richard H Wiggins; John M Hoffman; Kathryn A Morton
Journal:  Cancers (Basel)       Date:  2022-05-29       Impact factor: 6.575

2.  Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial.

Authors:  Mitchell Machtay; Fenghai Duan; Barry A Siegel; Bradley S Snyder; Jeremy J Gorelick; Janet S Reddin; Reginald Munden; Douglas W Johnson; Larry H Wilf; Albert DeNittis; Nancy Sherwin; Kwan Ho Cho; Seok-Ki Kim; Gregory Videtic; Donald R Neumann; Ritsuko Komaki; Homer Macapinlac; Jeffrey D Bradley; Abass Alavi
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

3.  [Oncologic imaging: indications for and limitations of modern cross-sectional imaging techniques].

Authors:  M E Mayerhoefer; A Ba-Ssalamah; H Prosch
Journal:  Radiologe       Date:  2013-04       Impact factor: 0.635

Review 4.  Management of malignant pleural effusion.

Authors:  Jack A Kastelik
Journal:  Lung       Date:  2013-01-13       Impact factor: 2.584

Review 5.  PET/CT imaging in lung cancer: indications and findings.

Authors:  Bruno Hochhegger; Giordano Rafael Tronco Alves; Klaus Loureiro Irion; Carlos Cezar Fritscher; Leandro Genehr Fritscher; Natália Henz Concatto; Edson Marchiori
Journal:  J Bras Pneumol       Date:  2015 May-Jun       Impact factor: 2.624

Review 6.  The utility of positron emission tomography in the treatment planning of image-guided radiotherapy for non-small cell lung cancer.

Authors:  Alexander Chi; Nam P Nguyen
Journal:  Front Oncol       Date:  2014-10-07       Impact factor: 6.244

Review 7.  Advances in electronic-nose technologies for the detection of volatile biomarker metabolites in the human breath.

Authors:  Alphus D Wilson
Journal:  Metabolites       Date:  2015-03-02

8.  PET/CT used in the evaluation of pulmonary nodules suspicious for lung cancer in regions where infectious lung disease is endemic: to be or not to be?

Authors:  Bruno Hochhegger
Journal:  Radiol Bras       Date:  2016 May-Jun

Review 9.  Assessment, origin, and implementation of breath volatile cancer markers.

Authors:  Hossam Haick; Yoav Y Broza; Pawel Mochalski; Vera Ruzsanyi; Anton Amann
Journal:  Chem Soc Rev       Date:  2013-12-04       Impact factor: 54.564

Review 10.  PET/CT in the staging of the non-small-cell lung cancer.

Authors:  Fangfang Chao; Hong Zhang
Journal:  J Biomed Biotechnol       Date:  2012-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.